The Protein Expression Market was valued at USD 3.75 billion in 2024, and is projected to reach USD 5.62 billion by 2030, rising at a CAGR of 7.17%. The increasing research in proteomics and genomics, the rising incidence of chronic diseases, and escalating demand for biologic products around the globe are enhancing the demand for protein expression, which is likely to drive the market. For instance, in April 2022, in a research published on Frontiers Media S.A., researchers differentially expressed 22 proteins to identify potential diagnostic biomarkers for Multiple Sclerosis (MS).
An increase in R&D investments by the players is estimated to have a considerable impact on the usage of protein expression. In August 2022, the managing director of Biocon Biologics stated in one of his interviews that the overall cost of the R&D is 12-14% of revenues. The investment is essential to build a sustainable portfolio of around 20 biosimilar molecules and the company is anticipated to launch at least once every 1-2 years. The approximate cost of developing these molecules is USD 50-100 million.
Other determinants such as rapid acceleration in the demand for protein therapeutics and government investment in the applications of the protein expression industry are also supporting the market growth. For instance, in May 2022, Proteomics International Laboratories was awarded approximately USD 286,833 funding from the Australian Government under the Medical Research Future Fund (MRFF) initiative. The funding is expected to support the manufacturing of the PromarkerD test in Australia. Such financial assistances are likely to supplement the market growth in the coming years.
The outbreak of the COVID-19 pandemic developed the urge to profile and conduct differential gene expression analyses on COVID-19 patients. Research published in Briefings in Bioinformatics, March 2021, employed the data of protein-drug interaction to identify the prospective drugs for COVID-19. As a result, the usage of the process is projected to upsurge during the COVID-19 pandemic and contribute to market growth.
The growing requirement for personalized therapy and vaccine is expected to be the key factor fueling the market growth during the forecast period. For instance, in January 2022, Amgen announced a collaboration with Generate Biomedicines to discover and develop protein therapeutics for various areas. The companies are estimating the worth of this collaboration around USD 1.9 billion.
The increasing development of recombinant proteins for industrial use, such as the production of food and beverages, is anticipated to boost the use of protein expression in the non-healthcare sector. However, the retail pricings of recombinant proteins for industrial and pharmaceutical uses are drastically different as pharmaceutical proteins are sold for billions of dollars per kg, while industrial proteins for tens of dollars per kg. R&D, clinical trials, and patents are the additional requirements of pharmaceutical proteins.
This product will be delivered within 2 business days.
An increase in R&D investments by the players is estimated to have a considerable impact on the usage of protein expression. In August 2022, the managing director of Biocon Biologics stated in one of his interviews that the overall cost of the R&D is 12-14% of revenues. The investment is essential to build a sustainable portfolio of around 20 biosimilar molecules and the company is anticipated to launch at least once every 1-2 years. The approximate cost of developing these molecules is USD 50-100 million.
Other determinants such as rapid acceleration in the demand for protein therapeutics and government investment in the applications of the protein expression industry are also supporting the market growth. For instance, in May 2022, Proteomics International Laboratories was awarded approximately USD 286,833 funding from the Australian Government under the Medical Research Future Fund (MRFF) initiative. The funding is expected to support the manufacturing of the PromarkerD test in Australia. Such financial assistances are likely to supplement the market growth in the coming years.
The outbreak of the COVID-19 pandemic developed the urge to profile and conduct differential gene expression analyses on COVID-19 patients. Research published in Briefings in Bioinformatics, March 2021, employed the data of protein-drug interaction to identify the prospective drugs for COVID-19. As a result, the usage of the process is projected to upsurge during the COVID-19 pandemic and contribute to market growth.
The growing requirement for personalized therapy and vaccine is expected to be the key factor fueling the market growth during the forecast period. For instance, in January 2022, Amgen announced a collaboration with Generate Biomedicines to discover and develop protein therapeutics for various areas. The companies are estimating the worth of this collaboration around USD 1.9 billion.
The increasing development of recombinant proteins for industrial use, such as the production of food and beverages, is anticipated to boost the use of protein expression in the non-healthcare sector. However, the retail pricings of recombinant proteins for industrial and pharmaceutical uses are drastically different as pharmaceutical proteins are sold for billions of dollars per kg, while industrial proteins for tens of dollars per kg. R&D, clinical trials, and patents are the additional requirements of pharmaceutical proteins.
Protein Expression Market Report Highlights
- The mammalian cell segment held the largest market share of 37.57% in 2024.
- In 2024, reagents segment dominated the market with a leading market share of 44.20%.
- The therapeutic segment held the highest market share with 43.47% in 2024.
- The pharmaceutical and biotechnological companies segment held the maximum market share in 2024 with 43.46%.
- North America's protein expression industry dominated the market with 40.88% share in 2024.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Protein Expression Market Variables & Trends
Chapter 4. Protein Expression Market: Expression Systems Estimates & Trend Analysis
Chapter 5. Protein Expression Market: Product Estimates & Trend Analysis
Chapter 6. Protein Expression Market: Application Estimates & Trend Analysis
Chapter 7. Protein Expression Market: End Use Estimates & Trend Analysis
Chapter 8. Protein Expression Market: Regional Estimates & Trend Analysis by Expression Systems, Product, Application, and End Use
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Protein Expression market report include:- Agilent Technologies, Inc.
- Bio-Rad Laboratories
- Thermo Fisher Scientific, Inc.
- Merck Millipore
- New England BioLabs, Inc.
- Promega Corporation
- QIAGEN
- Takara Bio, Inc.
- Oxford Expression Technologies
- Lucigen Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.75 Billion |
| Forecasted Market Value ( USD | $ 5.62 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
